The Ministry of Health and Family Welfare has proposed significant amendments to the Drugs Rules, 1945 aimed at simplifying the import of drugs for analytical and non-clinical testing while revising residual shelf-life requirements for imported medicines. The proposed reforms are expected to enhance ease of doing business, reduce compliance burden, promote pharmaceutical R&D, and improve supply chain efficiency without compromising patient safety.